Please use this identifier to cite or link to this item: https://doi.org/10.1093/annonc/mds067
Title: Targeting triple-negative breast cancer: Optimising therapeutic outcomes
Authors: Gelmon, K.
Dent, R. 
Mackey, J.R.
Laing, K.
Mcleod, D.
Verma, S.
Keywords: Basal like
Breast cancer
Cancer treatment
Systematic review
Targeted therapy
Triple negative
Issue Date: Sep-2012
Source: Gelmon, K., Dent, R., Mackey, J.R., Laing, K., Mcleod, D., Verma, S. (2012-09). Targeting triple-negative breast cancer: Optimising therapeutic outcomes. Annals of Oncology 23 (9) : 2223-2234. ScholarBank@NUS Repository. https://doi.org/10.1093/annonc/mds067
Abstract: Background: Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer (BC) defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2. It is highly heterogeneous and displays overlapping characteristics with both basal-like and BC susceptibility gene 1 and 2 mutant BCs. This review evaluates the activity of emerging targeted agents in TNBC. Design: A systematic review of PubMed and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with targeted and platinum-based therapies. Results and Discussion: Our review identified TNBC studies of agents with different mechanisms of action, including induction of synthetic lethality and inhibition of angiogenesis, growth, and survival pathways. Combining targeted agents with chemotherapy in TNBC produced only modest gains in progression-free survival, and had little impact on survival. Six TNBC subgroups have been identified and found to differentially respond to specific targeted agents. The use of biological preselection to guide therapy will improve therapeutic indices in target-bearing populations. Conclusion: Ongoing clinical trials of targeted agents in unselected TNBC populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target-selected populations. © The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Source Title: Annals of Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/126590
ISSN: 09237534
DOI: 10.1093/annonc/mds067
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

84
checked on Apr 2, 2018

WEB OF SCIENCETM
Citations

76
checked on Feb 27, 2018

Page view(s)

16
checked on Apr 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.